核酸逆转录酶抑制增强了COVID-19患者的血小板生产和巨核细胞成熟
Yubin Li1, Juan Wang2, Bingqian Huang1
1Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong, China.
British journal of haematology
|February 11, 2025
概括
某些抗病毒药物,如阿兹武丁,可能会改善COVID-19患者的血小板计数. 这项研究探讨了这些治疗方法如何影响2019年冠状病毒病 (COVID-19) 患者的血小板水平和血小板产量.
科学领域:
- 血液学 血液学 血液学
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 冠状病毒疾病2019 (COVID-19) 是一种影响造血系统的系统性感染.
- 在COVID-19患者中,血小板缺血与严重疾病和死亡率相关.
- 抗病毒药物对COVID-19中血小板计数的影响在很大程度上是未被探索的.
研究的目的:
- 评估抗病毒药物对住院COVID-19患者血小板质量的影响.
- 为了研究亚兹丁诱导的血小板升高的体外机制.
- 探索COVID-19中血小板缺血的潜在治疗应用.
主要方法:
- 对177名住院的COVID-19患者进行了回顾性研究,这些患者接受了阿兹武丁,尼尔马特里尔维尔-里托纳维尔或没有抗病毒治疗.
- 使用MEG-01细胞系进行体外实验,以评估阿兹武丁对血小板和巨核细胞产生的影响.
- 用RNA测序分析阿兹武丁治疗细胞中的基因表达变化.
主要成果:
- 与对照组相比,接受阿兹武丁或尼马特里尔维尔-里托纳维尔治疗的患者的血小板数增加显著更高.
- 阿兹丁显示血小板数的升高比尼尔马特里尔维尔-里托纳维尔更为严重.
- 在体外,阿兹武丁促进了巨核细胞的多化和血小板释放,调节了VWF,TUBB1,GP1BA和PI3K/AKT和JAK/STAT通路.
结论:
- 核酸逆转录酶抑制可能会增强COVID-19患者的血小板生产和巨核细胞成熟.
- 阿兹武丁在触发血小板释放方面显示出潜力,并可能为COVID-19相关的血小板缩提供治疗策略.
- 在COVID-19的背景下,抗病毒疗法代表了管理血小板缺血的潜在途径.
更多相关视频
10:32Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
Published on: August 24, 2015
13.5K
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
468
相关概念视频
01:18Structure and Function of Platelets
959
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
959
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461